New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Tue, 09/17/2024 – 19:04
Read more about FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- ea…
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis
Mon, 09/16/2024 – 10:19
Read more about Novartis Kisqali® shows deepening…
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
arcticnovartis
Wed, 08/28/2024 – 07:19
Read more about Novartis twice-yearly* Le…
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis
Thu, 08/08/2024 – 01:34
Read more about Novartis receiv…
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
arcticnovartis
Mon, 07/29/2024 – 18:04
Read more about Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly …
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis erzielt im zweiten Quarta…
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis a poursuivi…
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis continues to deliver strong sales growth and core margin expansi…